object
review
novel
deliveri
platform
base
bacteriophag
viruslik
particl
vlp
includ
introduct
structur
potenti
deliveri
platform
expect
use
medicin
field
bacteriophag
vlp
nanoparticl
devoid
viral
genet
materi
selfassembl
coat
protein
icosahedr
capsid
novel
deliveri
platform
possess
numer
featur
make
suitabl
attract
target
deliveri
rna
dna
epitop
peptid
drug
within
protein
capsid
short
novel
deliveri
platform
vlp
suitabl
deliveri
target
agent
hold
promis
use
diagnost
vaccin
therapeut
modal
viruslik
particl
vlp
nanoparticl
devoid
viral
genet
materi
usual
form
one
sever
structur
proteinshav
extern
structur
antigen
similar
nativ
virus
recent
consider
effort
devot
construct
vlp
make
attract
possibl
http
elsevi
bv
right
reserv
nanocarri
carrico
et
al
kovac
et
al
wu
et
al
combin
good
safeti
profil
strong
immunogen
vlp
expect
gain
widespread
use
numer
field
vitro
diagnost
vaccin
therapeut
modal
vlp
construct
virus
belong
famili
zeltin
among
vlpsan
icosahedr
capsid
selfassembl
copi
singl
coat
protein
cp
measur
nm
diameterrepres
novel
deliveri
platform
becam
hot
research
area
within
sever
year
attract
featur
first
vlp
offer
effect
conveni
way
packag
deliv
rna
dna
epitop
peptid
drug
within
bacteriophag
capsid
wei
et
al
wu
et
al
zhang
et
al
b
second
excel
adjuv
properti
thu
induc
innat
cognat
immun
respons
addit
safer
effect
tradit
vaccin
deriv
attenu
inactiv
infecti
viral
strain
furthermor
capabl
tissuespecif
target
modif
ligand
featur
ensur
target
agent
carri
vlp
effect
clinic
applic
vlp
perhap
excit
featur
main
applic
belong
field
vaccin
develop
seri
research
find
show
vlpbase
vaccin
effect
induc
innat
cognat
immun
respons
use
specif
prevent
intervent
diseas
footandmouth
diseas
bittl
et
al
dong
et
al
van
lierop
et
al
wong
et
al
prostat
cancer
li
et
al
ill
caus
human
papilloma
viru
hpv
tumban
et
al
anoth
import
applic
vlp
therapeut
modal
particl
deliv
drug
biolog
specif
tissu
ashley
et
al
pan
et
al
yao
et
al
moreov
packag
specif
rna
molecul
recombin
research
construct
socal
armor
rna
structur
similar
nativ
viru
concentr
alreadi
calibr
armor
rna
use
standard
calibr
detect
correspond
nativ
virus
valid
experi
help
control
da
et
al
zhan
et
al
object
review
novel
deliveri
platform
base
bacteriophag
vlp
includ
introduct
structur
potenti
deliveri
platform
expect
use
medicin
field
icosahedr
rna
bacteriophag
triangul
number
crystallograph
structur
solv
resolut
fig
borodavka
et
al
golmohammadi
et
al
et
al
et
al
genom
bacteriophag
positivesens
singlestrand
rna
molecul
nucleotid
encod
four
protein
major
coat
protein
cp
matur
protein
aprotein
replicas
rna
polymeras
necessari
genom
multipl
lysi
protein
fig
cp
make
bulk
bacteriophag
assembl
icosahedr
structur
nm
diamet
cp
molecul
first
form
dimer
dimer
bind
rna
hairpin
undergo
alloster
conform
chang
fg
loop
region
bleckley
schroeder
form
asymmetr
ab
dimer
rather
symmetr
cc
dimer
borodavka
et
al
fg
loop
b
conform
cp
surround
fivefold
vertic
icosahedron
c
conform
interdigit
threefold
vertic
icosahedron
thu
form
icosahedron
ab
dimer
cc
dimer
et
al
eventu
bacteriophag
form
simpl
ribonucleoprotein
structur
compos
cp
molecul
three
quasiequival
conform
cp
differ
primarili
conform
fg
loop
loop
subunit
similar
subunit
c
extend
conform
interact
capsid
threefold
axe
b
subunit
loop
bent
back
toward
globular
core
subunit
interact
b
loop
particl
fivefold
axe
fig
et
al
vitro
mastico
et
al
stockley
et
al
vivo
knoll
hohn
cp
molecul
capabl
selfassembl
capsid
rare
case
aberr
form
capsid
also
document
knoll
hohn
selfassembl
bacteriophag
discuss
know
bacteriophag
assembl
copi
cp
monodispers
icosahedr
capsid
diamet
nm
mastico
et
al
stockley
et
al
gener
final
fulli
form
capsid
repres
state
lowest
free
energi
compon
protein
nucleic
acid
therefor
assembl
final
fulli
form
vlp
stabl
structur
featur
form
basi
deliveri
kind
target
agent
regard
selfassembl
stockley
et
al
report
assembl
bacteriophag
achiev
via
interact
bacteriophag
cp
sequencespecif
socal
pac
site
say
rna
genom
special
function
structur
encapsid
insid
viru
particl
borodavka
et
al
rolfsson
et
al
show
cp
rna
act
mutual
chaperon
alter
conform
format
complex
contextspecif
way
capsid
shell
grow
initi
complex
toropova
et
al
toropova
et
al
report
encapsid
rna
well
order
form
two
layer
insid
icosahedr
viral
particl
dykeman
et
al
state
symmetri
icosahedron
locat
rna
hairpin
ab
dimer
point
possibl
assembl
mechan
aseri
hairpin
genom
thu
accord
find
cpbind
rna
hairpin
may
play
import
role
assembl
viru
particl
correct
size
symmetri
basnak
et
al
kone
et
al
morton
et
al
stockley
et
al
nonetheless
mani
viral
cp
assembl
absenc
rna
ie
around
nonvir
rna
polyanion
cadenanava
et
al
hu
et
al
even
nanoparticl
chen
et
al
accept
mechan
underli
assembl
vlp
mostli
repres
proteincentr
model
word
viral
protein
key
compon
process
assembl
vlp
zlotnick
mukhopadhyay
b
acteriophag
excel
model
studi
factor
affect
capsid
stabil
sever
factor
includ
physicochem
one
temperatur
ph
ionic
strength
structur
one
mutationsin
cp
affect
vlp
stabil
extent
one
experi
temperatur
stabil
plevka
et
al
found
melt
temperatur
phage
wildtyp
vlp
c
stonehous
stockley
report
particl
withstand
temperatur
c
capsid
detect
howev
temperatur
increas
l
c
order
determin
role
rna
capsid
stabil
experi
repeat
wildtyp
phage
particl
prepar
electron
microscopi
way
empti
capsid
similar
result
obtain
denatur
temperatur
show
rna
exerta
substanti
influenc
thermal
stabil
capsid
influenc
salt
natur
organ
matter
stabil
bacteriophag
studi
mylon
et
al
found
aggreg
induc
within
reason
kinet
time
frame
presenc
monoval
electrolyt
licl
nacl
kcl
situat
observ
even
salt
concentr
greater
hand
aggreg
solut
contain
dival
electrolyt
eg
ca
find
point
transit
repuls
attract
interact
among
viru
particl
monovalent
replac
dival
one
addit
thermal
saltrel
characterist
ph
may
strong
physicochem
influenc
stabil
studi
show
bacteriophag
stay
stabl
ph
becom
less
stabl
ph
decreas
da
poian
et
al
lago
et
al
sugiyama
et
al
addit
earli
dubovi
aker
found
decreas
recoveri
phage
prehumidif
anaerosol
sampl
collect
pepton
ad
spraymedium
stonehous
stockley
indic
wide
rang
amino
acid
substitut
toler
even
intermolecular
interfac
modest
effect
overal
stabil
substitut
howev
could
result
problem
cp
fold
stabil
thu
chang
amino
acid
sequenc
protein
may
lead
function
chang
effect
sitedirect
mutagenesi
cp
assembl
vlp
studi
conduct
stonehous
stockley
show
three
mutant
thermal
stabil
ident
wildtyp
cp
anoth
group
mutant
show
small
signific
c
increas
denatur
temperatur
third
group
show
c
decreas
denatur
temperatur
anoth
experi
peabodi
found
mutant
among
five
select
amino
acid
substitut
produc
signific
quantiti
solubl
cp
assembl
particl
electrophoret
mobil
wildtyp
viru
addit
comparison
wildtyp
capsid
stabil
decreas
mutat
cp
locat
fg
loop
axblom
et
al
peabodi
eli
stonehous
et
al
mean
genet
engin
two
differ
polypeptid
recombin
easili
earli
peabodi
lim
fuse
two
copi
cp
gene
remov
stop
codon
first
gene
second
residu
serin
second
copi
final
coval
cp
dimer
ccpd
gene
encod
amino
acid
residu
ccpd
molecul
found
assembl
vlp
particl
indistinguish
vlp
assembl
wildtyp
cp
resolut
electron
microscop
anoth
studi
show
wildtyp
ccpd
particl
stabl
dimer
wildtyp
subunit
peabodi
peabodi
lim
even
though
appear
similar
diamet
plevka
et
al
initi
report
form
nonvir
deliveri
system
wei
et
al
wu
et
al
target
specif
cell
type
via
chemic
coval
conjug
ligand
ashley
et
al
brown
et
al
bacteriophag
vlp
shown
mani
featur
deliveri
platform
one
hand
particl
prepar
easili
mean
recombinantprotein
technolog
hand
capsid
interact
pac
site
rna
dna
packag
target
rna
dna
locat
terminu
pac
site
thu
protect
target
rna
dna
degrad
nucleas
zhan
et
al
zhang
et
al
b
capabl
offer
effect
conveni
way
packag
kind
agent
way
deliveri
target
cell
vlp
hold
great
promis
novel
deliveri
platform
diagnost
vaccinerel
therapeut
purpos
fig
earli
studi
mrna
vaccin
becam
hot
area
research
direct
inject
nake
synthet
mrna
proven
feasibl
could
induc
antigenspecif
immun
respons
clinic
set
therefor
vaccinebas
mrna
open
new
avenu
develop
nextgener
vaccin
rittig
et
al
addit
mrna
vaccin
also
consid
effici
altern
protein
dna
vaccin
good
antigen
poten
possess
sever
featur
make
attract
potenti
nanocarri
passiv
target
drug
deliveri
effect
certain
diseas
anim
model
adapt
pan
et
al
b
e
vlpbase
rna
dna
armor
rna
dna
owe
structur
similar
nativ
rna
viru
good
biosafeti
recombin
vlp
wide
use
control
standard
calibr
assay
virus
tial
immunostimulatori
properti
scheel
et
al
also
owe
safeti
low
cost
high
puriti
van
lint
et
al
known
nake
mrna
easili
degrad
rnase
instabl
limit
practic
applic
ulmer
et
al
sever
approach
liposomeentrap
mrna
martinon
et
al
selfrepl
mrna
ying
et
al
mrnacoat
gold
particl
qiu
et
al
vitro
mrnatransfect
dendrit
cell
dc
gardner
et
al
perch
et
al
develop
improv
intracellular
stabil
translat
efficaci
mrna
nevertheless
approach
offer
perfect
carrier
deliveri
first
greatest
challeng
still
rel
instabl
mrna
owe
degrad
preval
rnase
besid
high
cost
gold
particl
gene
gun
inconveni
set
administr
experiment
anim
hinder
develop
ballist
deliveri
mrna
vaccin
furthermor
vitro
mrnatransfect
dc
use
cancer
treatment
clinic
turn
expens
van
lint
et
al
let
alon
scarciti
sourc
autolog
dc
disadvantag
hamper
practic
applic
develop
mrna
vaccin
thu
high
demand
simpl
safe
effici
stabl
inexpens
method
deliveri
mrna
vlpbase
rna
approach
util
develop
mrna
vaccin
resist
rapid
extracellular
degrad
fig
highli
specif
interact
cp
pac
site
target
mrna
packag
cp
bacteriophag
kept
stabl
within
h
uhlenbeck
therefor
mrna
deliveri
vivo
requir
complic
procedur
directli
target
antigenpres
cell
may
prefer
sever
studi
shown
mrna
vaccin
effect
protect
prostat
cancer
deliveri
platform
use
johnson
et
al
demonstr
prostat
acid
phosphatas
pap
mrna
vaccin
could
induc
papspecif
antibodi
tcell
immun
respons
wherea
pap
dna
vaccin
could
job
without
adjuv
granulocytemacrophag
colonystimul
factor
gmcsf
mockey
et
al
report
hpapgmcsf
mrna
vaccinewhich
first
show
prophylact
potenti
protect
mice
prostat
cancerprov
better
prevent
effect
liposomeencapsul
mrna
vaccin
mockey
et
al
zhou
et
al
effect
nake
mrna
vaccin
kreiter
et
al
nevertheless
encapsul
mrna
stabl
nake
mrna
protect
cp
studi
li
et
al
indic
vlpbase
hpapgmcsf
mrna
vaccin
could
suppress
prostatictumor
growth
mice
suggest
vaccin
may
evok
effici
immun
respons
within
short
period
promis
treatment
prostat
tumor
studi
hpap
mrna
vaccin
inferior
hpapgmcsf
mrna
vaccin
observ
mean
gmcsf
good
adjuvant
effect
activ
immun
system
immunolog
epitop
also
known
antigen
determin
part
antigen
recogn
immun
system
particular
antibodi
b
cell
cell
elicit
adapt
immun
respons
nonvir
deliveri
system
vlp
design
deliv
epitop
peptid
clinic
purpos
first
insert
dna
oligonucleotid
uniqu
site
gene
vlp
present
epitop
peptid
immun
system
mastico
et
al
peabodi
et
al
wei
et
al
cours
difficult
elicit
desir
antibodi
respons
specif
epitop
peptid
meloen
et
al
partido
steward
furthermor
vlp
present
viral
antigen
dens
repetit
array
known
highli
stimulatori
immunocyt
bachmann
et
al
milich
et
al
addit
compar
vlp
platform
vlp
advantag
good
stabil
proper
size
effect
present
viral
antigen
bundi
et
al
vlp
use
platform
present
epitop
major
case
approach
implement
modif
vlp
gene
sequenc
fusion
protein
vlp
compon
foreign
epitop
assembl
vlp
express
protein
featur
present
target
epitop
immun
system
fig
may
lead
widespread
use
clinic
practic
one
known
clinic
applic
vlp
vaccin
protect
footandmouth
diseas
viru
fmdv
fmdv
genom
singlestrand
posit
sens
rna
contain
uniqu
open
read
frame
encod
four
structur
protein
acharya
et
al
studi
confirm
epitop
peptid
also
known
induc
neutral
antibodi
also
fmdvspecif
cell
bittl
et
al
dong
et
al
van
lierop
et
al
wong
et
al
studi
mean
vlp
may
offer
protect
fmdv
vaccin
also
use
prevent
infect
hpv
current
hpv
vaccin
deriv
vlp
consist
hpv
major
capsid
protein
develop
secondgener
hpv
vaccin
base
hpv
minor
capsid
protein
tumban
et
al
insert
hpv
peptid
n
terminu
cp
bacteriophag
via
genet
recombin
found
vlpbase
vaccin
target
hpv
elicit
broadli
crossreact
crossprotect
antibodi
heterolog
hpv
thu
vlp
platform
recombin
could
serv
basi
broadli
protect
secondgener
hpv
vaccin
mirna
type
noncod
rna
bind
untransl
region
target
mrna
caus
degrad
translat
suppress
power
generegulatori
role
mirna
well
recogn
present
mirnabas
therapeut
strategi
shown
effect
experiment
tumor
model
type
treatment
may
effect
regulatori
mechan
singl
mirna
affect
hundr
target
multipl
pathway
rather
one
two
transcript
selbach
et
al
owe
mani
limit
howev
rapid
extracellular
degrad
necess
reliabl
deliveri
system
capabl
transfer
mirna
intracellular
space
without
cytotox
davidson
mccray
wang
et
al
develop
effici
mirna
deliveri
system
challeng
number
approach
mirna
deliveri
involv
use
viral
nonvir
vector
system
also
explor
davidson
mccray
nonetheless
typic
low
transduct
effici
possibl
cytotox
integrationinduc
tumorigenesi
alway
concern
plasmid
viral
vector
use
mirna
express
davidson
mccray
therefor
novel
attract
deliveri
system
recent
becam
focu
research
attent
field
mirna
deliveri
deliveri
vlp
mirna
use
gene
therapi
fig
studi
show
sever
known
mirna
potent
capac
gene
regul
ceribelli
et
al
dai
ahm
among
mirna
mirna
import
neg
regul
acut
respons
activ
innat
immunityact
effect
inhibitor
autoimmun
myeloprolifer
cancer
boldin
et
al
li
et
al
tang
et
al
overexpress
effect
suppress
express
target
gene
protein
pan
et
al
tang
et
al
report
express
reduc
peripher
blood
mononuclear
cell
pbmc
patient
system
lupu
erythematosu
sle
boldin
et
al
found
ablat
gene
mice
result
sever
advers
immunesystemrel
phenotyp
lead
prematur
death
studi
also
demonstr
level
mice
deliveri
via
first
significantli
increas
mirna
exert
therapeut
action
lupuspron
mice
via
inhibit
product
pathogen
autoantibodi
word
treatment
vlp
profound
effect
lupuspron
bxsb
mice
upregul
matur
caus
signific
downregul
autoantibodi
total
igg
proinflammatori
cytokin
includ
pan
et
al
confirm
induct
dysregul
mirna
vlpbase
deliveri
system
may
lead
novel
therapeut
intervent
sle
moreov
studi
yao
et
al
demonstr
osteoclastogenesi
inhibit
cell
precursor
mean
system
transport
human
pbmc
result
number
osteoclast
decreas
markedli
bone
resorpt
assay
demonstr
inhibit
activ
thu
deliveri
system
use
induc
overexpress
inhibit
differenti
function
osteoclast
vlp
possess
sever
featur
make
attract
potenti
nanocarri
passiv
target
drug
deliveri
fig
selfassembl
vlp
load
drug
even
drug
greaterthanaverag
molecular
weight
suffici
volum
interior
caviti
deliv
drug
specif
target
cell
studi
ashley
et
al
macromolecular
drug
candid
doxorubicin
cisplatin
encapsid
specif
effici
insid
protect
cp
shell
first
coval
link
rna
oper
trigger
vitro
capsid
assembl
disassembl
cp
dimer
drug
packag
direct
toward
hepatocellular
carcinoma
coval
modificationof
outsid
surfac
ligand
receptormedi
endocytosi
eventu
select
kill
hepatocellular
carcinoma
cell
anoth
experi
brown
et
al
test
cytotox
analog
combin
monoclon
antibodi
packag
synthet
virionsagainst
breast
carcinoma
cell
express
antigen
result
show
slightli
toxic
free
lower
concentr
suggest
synthet
virion
enhanc
toxic
oligonucleotid
protect
degrad
nucleas
serum
enhanc
uptak
cell
diagnost
method
absolut
concentr
specif
rna
detect
high
sensit
specif
type
rna
calibr
known
concentr
play
core
role
reliabl
detect
rna
kind
rna
one
hand
may
serv
control
valid
experi
hand
serv
quantit
standard
calibr
sampl
measur
hand
kind
rna
easili
degrad
rnase
vitro
possibl
place
rna
longterm
storag
prevent
degrad
recent
year
recombin
vlp
packag
rna
socal
armor
rna
develop
use
control
standard
calibr
stevenson
et
al
fig
diagnost
procedur
follow
reason
first
possess
structur
similar
nativ
rna
viru
serv
substitut
nativ
viru
extract
procedureand
thu
dramat
reduc
error
rate
detect
viru
addit
rna
particl
rnase
resist
virtu
encapsul
within
moreov
pathogen
experi
particl
replic
armor
rna
base
vlp
use
detect
variou
virus
human
immunodefici
viru
paslosk
et
al
sever
acut
respiratori
syndrom
coronaviru
drosten
et
al
enterovirus
beld
et
al
donia
et
al
avian
influenza
viru
da
et
al
measl
viru
zhang
et
al
b
ebola
viru
although
armor
rna
good
candid
rnaseresist
posit
control
standard
applic
limit
maxim
length
exogen
rna
packag
vlp
mean
exist
armoredrna
technolog
nevertheless
zhan
et
al
construct
long
armor
rna
contain
exogen
rna
use
detect
oneplasmid
doubleexpress
system
complet
resist
rnase
remain
stabl
normal
human
edtapreserv
plasma
c
least
month
yield
reproduc
linear
result
versant
rna
assay
addit
recent
studi
zhang
et
al
b
produc
armor
hepat
b
viru
hpv
dna
use
nucleicacid
assay
construct
confirm
stabl
homogen
noninfecti
nucleas
resist
safe
ship
studi
doublestrand
dna
kb
long
success
packag
capsid
high
reassembl
effici
first
success
use
bacteriophag
platform
encapsul
doublestrand
dna
armor
dna
may
becom
ideal
control
standard
use
clinic
laboratori
test
diagnost
hold
promis
vari
applic
especi
new
platform
product
assay
standard
dna
virus
accord
properti
vlp
particl
seem
ideal
carrier
deliveri
varieti
agent
note
larg
protein
domain
serv
antigen
may
pose
difficulti
display
insert
may
disrupt
vlp
assembl
case
chemic
conjug
may
solut
anoth
problem
deliveri
rna
within
vlp
vlp
immunogen
antibodi
respons
particl
may
interfer
deliveri
intend
destin
bacteriophag
vlp
selfassembl
cp
icosahedr
capsid
particl
offer
effect
conveni
way
packag
rna
dna
epitop
peptid
drug
bacteriophag
capsid
form
differ
kind
vlp
vlp
deliv
variou
kind
agent
good
safeti
profil
strong
immunogen
also
ensur
tissuespecif
target
determin
speci
viru
thu
vlp
possess
extens
prospect
practic
applic
promis
applic
vaccin
develop
therapeut
modal
besid
vlp
use
control
calibr
assay
nativ
virus
